|Day's Range||0.050 - 0.055|
|52 Week Range||0.030 - 0.090|
|PE Ratio (TTM)||-4.58|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Vancouver, British Columbia--(Newsfile Corp. - June 15, 2017) - iCo Therapeutics (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or "the Company"), today reported it will hold a pre IND meeting with the Division of Transplantation and Ophthalmology, US Food and Drug Administration (FDA) on June 21st, 2017. Discussions will focus on a proprietary dual action glaucoma asset with a novel mechanism of action that reduces intraocular pressure (IOP). The target is validated by literature and a ...
Vancouver, British Columbia--(Newsfile Corp. - June 12, 2017) - iCo Therapeutics (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or "the Company"), today reported the successful conclusion of pre-clinical studies involving its lead oral Amphotericin B candidate, including compelling safety data from its pivotal 14 day GLP (Good Laboratory Practices compliant) toxicology study.Data from its IND enabling 14 day GLP study conducted in Toronto, Ontario facilities revealed that oral administration of Amphotericin B at a dose levels of ...
The Vancouver, British Columbia-based company said it had a loss of less than 1 cent on a per-share basis. In the final minutes of trading on Wednesday, the company's shares hit 3 cents. A year ago, they ...